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Abstract
Epigenetic alterations relate to various human diseases, and developing inhibitors of Kme 
regulatory proteins is considered to be a new frontier for drug discovery. We were inspired by the 
known multicyclic ligands, UNC669 and UNC926, which are the first reported small molecule 
ligands for a methyl-lysine binding domain. We hypothesized that reducing the conformational 
flexibility of the key amine moiety of UNC669 would result in a unique set of ligands. Twenty-
five novel compounds containing a fused bi- or tricyclic amine or a spirocyclic amine were 
designed and synthesized. To gauge the potential of these amine-containing compounds to interact 
with Kme regulatory proteins, the compounds were screened against a panel of 24 protein 
methyltransferases. Compound 13 was discovered as a novel scaffold that interacts with SETD8 
and could serve as a starting point for the future development of PKMT inhibitors.
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Mounting evidence suggests that epigenetic alterations relate to various human diseases 
including inflammation, brain disorders, metabolic diseases, and cancer.1-3 One such 
epigenetic modification is histone lysine methylation. Protein lysine methyltransferases 
(PKMTs) catalyze the transfer of a methyl group from the cofactor S-adenosyl-L-methionine 
(SAM) to lysine residues of histone and non-histone substrates, leading to lysine mono-, di-, 
and/or trimethylation. Lysine methylation is reversible in that the methyl groups can be 
removed by either the Jumonji family of 2-oxoglutarate-dependent demethylases4 or the 
flavin dependent enzymes, lysine-specific histone demethylase 1 (LSD1) and LSD2.5 Lysine 
methylation has been identified at various positions of the histone tails, mainly on histone 3 
at lysine 4 (K4), K9, K27, K36, and K79, and on histone 4 at K20.6 All methylated forms of 
lysine are cationic at physiological pH, while trimethyllysine contains a fixed positive charge 
irrespective of its environment.
In contrast to the enzymes that install and remove the methyl groups on lysine, methyl-
lysine (Kme) readers recognize and bind the Kme marks non-covalently, most commonly via 
an interaction between the methyl-ammonium group and an aromatic cage in the protein. 
This binding interaction is largely the result of favorable cation-π and van der Waals 
interactions, while hydrophobic desolvation effects also contribute. Depending on the 
methylation state, nearby acidic residues in the binding pocket are also known to form salt 
bridges with the methylated lysine residue, offering an additional stabilizing effect.7, 8 Kme 
readers are categorized into three main families by their respective binding domains: the 
plant homeodomain (PHD) zinc finger proteins, the WD40 repeat domain-containing 
proteins, and the so-called Royal family of reader proteins, including tudor, chromo, Pro-
Trp-Trp-Pro (PWWP), and malignant brain tumor (MBT) domain-containing proteins.
Overall, histone lysine methylation can be associated with either transcriptional activation or 
repression. The mutation, overexpression, and aberrant regulation of Kme regulatory 
proteins have been linked to many diseases, especially cancer.3 For example, overexpression 
of the key developmental histone lysine methyltransferase, EZH2, has been observed in 
several types of leukemias and in various solid tumors.9 Thus, developing inhibitors of Kme 
regulatory proteins is considered to be a new frontier for drug discovery. Additionally, the 
exact biological mechanisms of many of these proteins still require elucidation, and 
therefore small molecule chemical probes would facilitate further study and understanding 
of their functions.10-12
We were initially inspired by the known multicyclic ligands, UNC669 (1a, Fig. 1a)13 and 
UNC926 (1b, Fig. 1b),14 which are the first reported small molecule ligands for a methyl-
lysine binding domain, specifically the second MBT domain of both L3MBTL1 and 
L3MBTL3. As shown in the high-resolution co-crystal structure of UNC669 and L3MBTL1 
(pdb 3P8H), the pyrrolidine amine makes a key hydrogen bond with aspartic acid D355 and 
the ligand also engages the aromatic binding cage (F379, W382, Y386; Fig. 1c). We 
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hypothesized that preparing a variety of amines with reduced conformational flexibility 
relative to the piperidine-pyrrolidine amine (Fig. 1a and 1b, red) may generally result in 
ligands with enhanced affinity for proteins that interact with methylated lysine.
Beyond targeting methyl-lysine regulatory proteins, nitrogen-based heterocycles are of 
broad interest in medicinal chemistry. Furthermore, compounds with fused ring systems and 
spirocyclic heterocycles have found applications as antibacterial drugs,15 antitumour 
drugs,16 5-HT2C receptor agonists,17 ChK1 kinase inhibitors,18 and CGRP receptor 
antagonists.19 In this article we describe the design and synthesis of a set of compounds 
containing fused bi- or tricyclic amines and spirocyclic amines that are well poised to both 
interact with Kme regulatory proteins as well as provide value to a number of medicinal 
chemistry efforts.
We designed 25 fused and spirocyclic amines (Fig. 2) that: (1) contain a basic amine, (2) are 
fragment-like in size (less than 200 g/mol), (3) are non-aromatic, and (4) contain a synthetic 
handle for further chemistry to attach the amines to a variety of scaffolds. Upon preparation, 
each amine was reacted with 3-bromobenzoyl chloride by the general synthetic route shown 
in Scheme 1. When necessary, protected amines were coupled to 3-bromobenzoyl chloride 
and subsequent deprotection gave the desired products. At this point, secondary amines 
could also be alkylated to give the corresponding tertiary or quaternary amine-containing 
compounds. In the end, this resulted in a unique set of fused and spirocyclic compounds (2–
26) well poised for screening efforts and future development, and their synthesis is discussed 
below.
While several of the proposed constrained amines or precursors of these amines were 
synthesized according to methods in the literature, a number of the amines including those 
of compounds 2, 3, 18, and 19 have not been reported previously. In the preparation of 
compounds 2 and 3, 1-benzyl-3-piperidone (27) was used as a starting material (Scheme 2). 
Treatment of 27 with allylamine gave the corresponding imine, and the crude product was 
then treated with allylmagnesium bromide to provide the aminodiene (28). Compound 29 
was obtained by protecting the secondary amino group of 28 as the trifluoroacetamide. 
Treatment of 29 with Grubbs catalyst in DCM gave spirocyclic compound 30. The 
trifluoroacyl group of compound 30 was converted to a Boc protecting group in two steps to 
generate 32. The key intermediate (33) was obtained by reduction of 32 with palladium. We 
coupled amine 33 to 3-bromobenzoyl chloride and removed the Boc group to provide target 
compound 2. Compound 3 was achieved via installation of a methyl group on the basic 
nitrogen of compound 2 via reductive amination. The Boc protected 1,9-diazaspiroundecane 
amine used to prepare compounds 4-6was similarly synthesized from 1-benzyl-4-
piperidone. 20 The reaction of 5 with methyl iodide gave the corresponding quaternary 
amine containing compound (6). It is possible that such quaternary amines may interact 
more favorably with slightly larger binding pockets such as those of Kme3 reader domains 
and methyltransferases that install the trimethyl mark.
The syntheses of the bi- or tricyclic amines of compounds 7-10 were initiated with the 
protection of aminoacetaldehyde dimethyl acetal as the ethyl carbamate, followed by 
alkylation with allyl bromide. After deprotection with formic acid, the desired aldehyde was 
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obtained. A 1,3-dipolar cycloaddition of the aldehyde and N-methylglycine, proline, 
piperidine-2-carboxylic acid, or N-benzylglycine provided the amines used to prepare 
compounds 7-10, respectively.17, 21 This racemic synthesis afforded the amine precursors of 
compounds 7–10 as cis racemates, as has been reported previously.17 We additionally 
prepared the 4-nitrobenzoyl analogue of compound 8 and confirmed its cis-configuration by 
single-crystal X-ray diffraction (Supplementary Figure 1). The fused cyclic amines of 
compounds 11 and 12 were synthesized with the common starting material, 3,3-
dimethoxypropan-1-amine, using a 1,3-dipolar cycloaddition as the key step, analogous to 
the preparation of compounds 7 and 10, respectively.22 Compounds 7 and 11 were obtained 
after deprotection of the benzyl group upon coupling to 3-bromobenzoyl chloride. 
Additionally, we prepared an analogue of compound 11 (containing two 4-nitrobenzoyl 
groups) and its cis-configuration was confirmed by single-crystal X-ray diffraction 
(Supplementary Figure 2).
The fused cyclic amine containing compounds 13-16 were synthesized from 2,3-
pyridinedicarboxylic acid. Dehydration of the pyridinedicarboxylic acid with acetic 
anhydride and then ammonolysis with benzyl ammonium gave 6-benzyl-5H-pyrrolo[3,4-
b]pyridine-5,7(6H)-dione. Hydrogenation with palladium gave key intermediate 6-
benzyltetrahydro-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione, and subsequent reduction by 
lithium aluminium hydride led to the protected bicyclic fused amine precursor used to 
prepare compounds 13-16.23 Key intermediate 6-benzyltetrahydro-5H-pyrrolo[3,4-
b]pyridine-5,7(6H)-dione was determined to be the cis racemate by comparison of the NMR 
spectra with previous literature reports.24 Compound 17 was prepared analogously to 
compound 16 from 3,4-pyridinedicarboxylic acid.22
Compounds 18 and 19 were prepared according to the sequence outlined in Scheme 3. First, 
compound 35 was converted to the corresponding oxime (36) which was subsequently 
oxidized with TFAA/H2O2 to give the Cbz protected 3-nitro piperidine (37). The nitro ester 
intermediate (38) was obtained by a Michael addition of 37 with methyl acrylate under mild 
conditions. Subsequent reduction of the nitro group by catalytic hydrogenation over Raney 
Nickel gave the corresponding amino intermediate, which spontaneously cyclized to the 
spirolactam (39). Reduction of 39 by lithium aluminium hydride lead to 7-methyl-1,7-
diazaspiro [4. 5] decane, which was subsequently acylated to give compound 18. 
Alternatively, methylation of the amide of 39 by iodomethane followed by Cbz deprotection 
with palladium provided intermediate 41, which could be converted to compound 19 by a 
similar reduction and acylation sequence. The diamine spirocycle scaffolds used to prepare 
compounds 20 and 21 were synthesized from Cbz-protected 4-nitropiperidine via the same 
route.25
The boc protected spirocyclic amines used in the preparation of compounds 22 and 23 were 
obtained by cyclization of 1-benzyl-4-piperidinone, or 1-benzyl-3-piperidinone in the case 
of 24, with ethyl cyanoacetate followed by hydrolysis and decarboxylation as reported 
previously.26 Finally, the methylated spirocyclic amines of compounds 25 and 26 were 
prepared utilizing a key double alkylation of ethyl cyanoacetate. Subsequent nitrile reduction 
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and lactamization to establish the first heterocyclic ring followed by imide formation with 
methyl amine and global reduction furnished the target spirodiamines.27
With a unique set of compounds in hand containing bi- or tricyclic fused ring systems or 
spirocyclic amines, we sought to investigate the ability of these compounds to interact with a 
panel of 24 lysine and arginine methyltransferases (Supplementary Table 1). The activity of 
each enzyme was initially measured in the presence of 50 μM compound using a 
radioactivity-based Scintillation Proximity Assay.28 Of the compounds screened, three 
reduced the enzymatic activity of the methyltransferase SETD8 to less than 50% that of the 
untreated enzyme (Table 1).
SETD8 is the sole PKMT known for the in vivo monomethylation of histone H4 lysine 20 
(H4K20),29, 30 and it has also been shown to monomethylate K382 of p53 and K248 of the 
proliferating cell nuclear antigen (PCNA).31, 32 This enzyme has been implicated in DNA 
damage response, cell cycle progression, and the silencing of euchromatic genes.33 Due to 
the growing interest in the perturbation of SETD8 activity with small molecules, a number 
of inhibitors of SETD8 have recently been discovered including the SAM-competitive 
inhibitor and marine natural product, nahuoic acid A,34 and the substrate competitive 
inhibitor, UNC0379 (Supplementary Figure 3).35 Most recently, Blum and coworkers 
reported three irreversible SETD8 inhibitors which exhibited modest selectivity and were 
active in cells.36
We next sought to confirm these results by determining the IC50 values of compounds 5, 6, 
and 13 for SETD8. While compounds 5 and 6 demonstrated no appreciable activity up to 
200 μM (Supplementary Figure 4), compound 13 showed robust but weak activity against 
SETD8 (IC50 = 39 ± 11 μM; Table 2 and Figure 3). Hoping to further characterize the 
activity of compound 13 for SETD8, we performed isothermal titration calorimetry (ITC) 
studies both in the presence and absence of S-Adenosyl-L-homocysteine (SAH). While 
significant binding was not observed, this is not overly surprising, as the ligand is inherently 
weak which prevents the ITC studies from being performed under optimal conditions to 
detect and quantify binding, particularly considering that prior reports suggest that we would 
expect a dissociation constant about 3-fold weaker than the observed IC50.35
In conclusion, we were inspired by the known multicyclic ligands, UNC669 and UNC926, 
and we hypothesized that reducing the conformational flexibility of the piperidine-
pyrrolidine amine would generate a novel set of nitrogen-based heterocyclic ligands well 
poised to engage the proteins that interact with methylated lysine, as well as provide value in 
other areas of medicinal chemistry. In order to explore this hypothesis further, we designed 
and synthesized a unique set of 25 compounds with bi- or tricyclic fused amines or 
spirocyclic heterocycles and a simple bromobenzene core. We then investigated the ability of 
this set of amine-containing compounds to interact with a panel of protein lysine and 
arginine methyltransferases, which led to the identification of compound 13 as a novel 
scaffold that interacts with SETD8. Despite its weak affinity, compound 13 serves as an 
attractive scaffold for further development as a SETD8 inhibitor. In addition, we believe that 
the set of constrained amines developed will find wide utility when incorporated into a 
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variety of diverse scaffolds, and we are presently expanding our compound set to be broadly 
screened against different classes of Kme regulatory proteins.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Structures of L3MBTL1/L3MBTL3 inhibitors. (a) Structure of UNC669. (b) Structure of 
UNC926. (c) Co-crystal structure of UNC669 with L3MBTL1 (pdb 3P8H).
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Figure 2. 
Structures of compounds containing bi- or tricyclic fused amines or spirocyclic heterocycles. 
The core structure of all final compounds is shown in Scheme 1.
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Figure 3. 
Compound 13 binds SETD8 with an IC50 of 39 ± 11 μM.
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Scheme 1. 
General procedure for target compound synthesis. (a) Et3N, DCM, 0 °C to rt.
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Scheme 2. 
Route to compounds 2 and 3. (a) i. 3-aminopropene, K2CO3, toluene, N2, 12 h; ii. 10% 
allylmagnesium bromide/Et2O, toluene, N2, 0 °C to rt, 8 h (two steps, 37%-45%); (b) TFAA, 
DMAP, DCM, 0 °C to rt, 21 h (82%); (c) Grubbs II, DCM, Ar, 24 h, (73%); (d) K2CO3, 
MeOH, reflux, 5 h, (98%); (e) (Boc)2O, MeCN, 3 d, (99%); (f) 10% Pd/C, HOAc, 
HCOONH4, MeOH, reflux, Ar, 5 h, (82%); (g) 3-bromobenzoyl chloride, Et3N, DCM, 0 °C 
to rt, 2 h, (95%); (h) i. CF3COOH, DCM, 2 h; ii. TEA, DCM, 4 h, (95%); (i) NaCNBH4, 
HCHO/H2O, HOAc, MeOH, 20 h, (85%).
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Scheme 3. 
Route to compounds 18 and 19. (a) NH2OH·HCl, CH3COONa, EtOH, 2 h (86%); (b) TFAA, 
30% H2O2, urea, NaHCO3, CH3CN, reflux, 11 h (33%-39%); (c) methyl acrylate, K2CO3, 
MeOH, 12 h (98%); (d) Raney Ni, H2, EtOH, 50 °C; (e) CH3I, NaH, THF, 19 h (97%); (f) 
Pd/C, H2, 24 h; (g) i. LiAlH4, THF, reflux, 12 h; ii. 3-bromobenzoyl chloride, Et3N, DCM, 
0 °C to rt, 2 h, (two steps, 56%-97%).
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Table 1
Structures of preliminary SETD8 hit compounds and percent SETD8 activity in the presence of 50 μM 
compound.
Compound Structure % SETD8 Activity
5 43
6 49
13 45
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Table 2
IC50 determination of compounds 5, 6, and 13 for SETD8.
Compound IC50 (μM) Hill Slope
5 >200 NA
6 >200 NA
13 39 ± 11 2
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